Eli Lilly & Co. (LLY)

89.73
0.16 0.18
NYSE : Health Technology
Prev Close 89.57
Open 89.60
Day Low/High 89.07 / 89.78
52 Wk Low/High 73.69 / 89.97
Volume 594.61K
Avg Volume 3.60M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 96.68B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.41%)

Latest News

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

New Lilly Diabetes Helpline To Assist People Seeking Solutions To Insulin Affordability

New Lilly Diabetes Helpline To Assist People Seeking Solutions To Insulin Affordability

Starting August 1, the Lilly Diabetes Solution Center will point people toward customized solutions based on personal circumstances

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

Even after Monday's rally, these stocks are terrific, says Jim Cramer. Here's how to play the great employment numbers.

Trimming Lilly on Strength

This is an opportunity to keep booking profits at what now will be our highest sale price to date.

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.

Weekly Roundup

In a holiday-shortened week, markets shrugged off trade tariffs, and welcomed a strong jobs report.

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

Buying NVDA, C...Trimming PYPL, LLY

We're funding our two buys by selling some PayPal and Lilly.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CODI, GMRE, HONE, KR, LLY, MJCO, OLP, SBGI, SNX, TBBK Downgrades: CMCM, EDN, GFF, GSM, HGT, SENEA, SENEB, STAA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Lilly Confirms Date And Conference Call For Second-Quarter 2018 Financial Results Announcement

Lilly Confirms Date And Conference Call For Second-Quarter 2018 Financial Results Announcement

INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018.

Lilly Announces Positive Top-Line Results For Second Phase 3 Study Of Taltz® (ixekizumab) In Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) For TNF Inhibitor-Experienced Patients

Lilly Announces Positive Top-Line Results For Second Phase 3 Study Of Taltz® (ixekizumab) In Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) For TNF Inhibitor-Experienced Patients

INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment...

AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days In Patients With Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)

AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days In Patients With Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)

INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality ™   (galcanezumab-gnlm) in patients with episodic and chronic migraine who had...

AHS 2018: Lilly Highlights Positive Phase 3 Results From The Largest Controlled Preventive Trial In Episodic Cluster Headache

AHS 2018: Lilly Highlights Positive Phase 3 Results From The Largest Controlled Preventive Trial In Episodic Cluster Headache

INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with Emgality ™ (galcanezumab-gnlm).

First-ever Study Of Lilly's Humulin® R U-500 Administered In An Insulin Pump Shows Improved A1C In People With Type 2 Diabetes

First-ever Study Of Lilly's Humulin® R U-500 Administered In An Insulin Pump Shows Improved A1C In People With Type 2 Diabetes

Study Results Evaluating Humulin R U-500 in Insulet Corporation's Omnipod® U-500™ Insulin Management System Presented at the American Diabetes Association 78th Scientific Sessions

Boehringer Ingelheim And Lilly Announce Positive Top-line Phase III Data Results For Empagliflozin As Adjunct To Insulin In Type 1 Diabetes

Boehringer Ingelheim And Lilly Announce Positive Top-line Phase III Data Results For Empagliflozin As Adjunct To Insulin In Type 1 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, June 25, 2018 /PRNewswire/ --  Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in...

Lilly To Present Phase 3 Data At AHS 2018 Highlighting Innovative Potential Treatments For Migraine And Cluster Headache

Lilly To Present Phase 3 Data At AHS 2018 Highlighting Innovative Potential Treatments For Migraine And Cluster Headache

INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the American...

Real-World Data Show Advantages In People Treated With Lilly's Once-Weekly Trulicity® (dulaglutide) Compared To Those Treated With Liraglutide And Exenatide QW

Real-World Data Show Advantages In People Treated With Lilly's Once-Weekly Trulicity® (dulaglutide) Compared To Those Treated With Liraglutide And Exenatide QW

Data showing improved effectiveness, adherence and persistence to be presented at the ADA's 78th Scientific Sessions®

Jardiance® Reduced Risk Of Kidney Disease Progression In Adults With Type 2 Diabetes And Established Cardiovascular (CV) Disease Independent Of Control Of Conventional CV Risk Factors

Jardiance® Reduced Risk Of Kidney Disease Progression In Adults With Type 2 Diabetes And Established Cardiovascular (CV) Disease Independent Of Control Of Conventional CV Risk Factors

- In separate analysis, Jardiance (empagliflozin) reduced risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce Potential Of Lilly's Ultra Rapid Lispro In People With Type 1 And Type 2 Diabetes

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce Potential Of Lilly's Ultra Rapid Lispro In People With Type 1 And Type 2 Diabetes

INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b...

Investigational Doses Of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise In Delivering Powerful Efficacy In People With Type 2 Diabetes

Investigational Doses Of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise In Delivering Powerful Efficacy In People With Type 2 Diabetes

Data from a Phase 2 trial will be presented for the first time at the ADA's 78th Scientific Sessions®

Weekly Roundup

Markets had a tumultuous week starting with increased trade war fears and ending with a modest oil production increase from OPEC.

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

Lilly Completes Acquisition Of ARMO BioSciences

Lilly Completes Acquisition Of ARMO BioSciences

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

Lilly Declares Third-Quarter 2018 Dividend

Lilly Declares Third-Quarter 2018 Dividend

INDIANAPOLIS, June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.

Weekly Roundup

Rate hikes and trade wars weighed on stocks this week.

TheStreet Quant Rating: B (Buy)